- Home
- RVSN vs CURX Comparison
RVSN vs CURX Comparison
Compare RVSN & CURX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RVSN | CURX |
|---|---|---|
| Founded | 2016 | 2018 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.9M | 7.5M |
| IPO Year | 2018 | 2024 |
Fundamental Metrics
Financial Performance| Metric | RVSN | CURX |
|---|---|---|
| Price | $2.93 | $4.83 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 15.1K | ★ 21.8K |
| Earning Date | 08-26-2026 | 09-09-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $169.00 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.17 | $0.21 |
| 52 Week High | $9.39 | $16.93 |
Technical Indicators
Market Signals| Indicator | RVSN | CURX |
|---|---|---|
| Relative Strength Index (RSI) | 28.31 | 56.62 |
| Support Level | $0.24 | $3.79 |
| Resistance Level | $5.19 | $5.27 |
| Average True Range (ATR) | 0.27 | 0.48 |
| MACD | -0.03 | 0.00 |
| Stochastic Oscillator | 8.92 | 79.80 |
Price Performance
Historical ComparisonAbout RVSN Rail Vision Ltd.
Rail Vision Ltd is an early commercialization stage technology company focused on railway safety systems using AI-integrated sensing systems. The company develops and commercializes proprietary, multi-spectral electro-optic platforms that provide extended-range situational awareness and real-time hazard detection. Using machine learning algorithms to identify and classify obstacles, the company's technology enhances safety, improves operational efficiency, and supports continuity across deployments.
About CURX Curanex Pharmaceuticals Inc
Curanex Pharmaceuticals Inc is engaged in discovering, developing, and commercializing botanical drugs for treating unmet medical needs in patients with inflammatory disease. Its compound, Phyto-N, is in preclinical research for six indications: ulcerative colitis, atopic dermatitis, COVID-19, type 2 diabetes, nonalcoholic fatty liver disease (NAFLD) and gout. Phyto-N, is a proprietary botanical extract with chemical components and pharmacological activities that harnesses potential anti-inflammatory properties of a medicinal plant.